PSMA PET for the Staging and Management of Hepatocellular Carcinoma

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 90

Sponsor: VA Office of Research and Development

Location: VA Greater Los Angeles Healthcare System, West Los Angeles, CA West Los Angeles California

Summary

This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.

Eligibility Criteria

Inclusion Criteria: * Adult patients age \>18 years from the VA medical system * Treatment-naïve patients with HCC with BCLC B or C disease Exclusion Criteria: * Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging * Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07019844). StuddyBuddy aggregates publicly available trial information.